Study study type
PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)
cemiplimab
EMPOWER lung1 (all population), 2021
  NCT03088540		RCTmNSCLC - L1 - all populationcemiplimabICCpatients with confirmed stage IIIB or IIICor stage IV squamous or non-squamous non-small-celllung cancer356 / 354some concern
 conclusif
  • demonstrated 32 % decrease in deaths (OS) (PE)
  • demonstrated 41 % decrease in progression or deaths (PFS) (PE)
  • demonstrated 1.2-fold increase in objective responses (ORR) (PE)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
cemiplimab
EMPOWER lung1 (PDL1>50%), 2021
  NCT03088540		RCTmNSCLC - L1 - PDL1 positivecemiplimabICCpatients with confirmed stage IIIB or IIICor stage IV squamous or non-squamous non-small-celllung cancer with PD-L1 expressed in at least 50% oftumour cells283 / 280some concern
 suggested
  • suggested 43 % decrease in deaths (OS) (PE)
  • suggested 46 % decrease in progression or deaths (PFS) (PE)

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons